Trump Signs Executive Order Endorsing Psychedelic Psilocybin and Ibogaine; Asks 'Can I Have Some, Please?'

Key Points:

• On April 18, 2026, President Donald Trump signed an executive order directing federal agencies to expedite the review, funding, and potential reclassification of psychedelic drugs like psilocybin and ibogaine for treating serious mental illnesses.
• The order instructs the FDA to issue National Priority Vouchers to qualifying psychedelic compounds with Breakthrough Therapy designation, enabling faster review processes, and allocates $50 million through ARPA-H to support state-level psychedelic research programs.
• It mandates the FDA and DEA to establish access pathways under the Right to Try Act for eligible patients and requires the Attorney General to initiate rescheduling reviews for psychedelics that complete Phase 3 trials and receive FDA approval.
• The policy is motivated by a public health crisis, highlighting rising suicide rates and the disproportionate impact on veterans, with over 6,000 veteran suicides annually; the Department of Veterans Affairs is already participating in psychedelic trials.
• While the order facilitates regulatory pathways, both psilocybin and ibogaine remain Schedule I substances, and significant safety concerns, especially cardiovascular risks with ibogaine, pose challenges to swift approval despite promising scientific research.